# **Special Issue**

# New Approaches to Spinal Cord-Related Diseases

# Message from the Guest Editor

We welcome submissions that present cutting-edge therapeutic strategies, including, but not limited to, stem cell-based therapies, neuromodulation techniques, and other experimental interventions targeting neural regeneration and functional restoration. Particular attention will be paid to the management of long-term neurological sequelae such as spasticity, neuropathic pain, and autonomic dysfunctions, which significantly affect patients' quality of life.

In addition, we encourage contributions exploring advanced neuroimaging and electrophysiological techniques for the assessment of spinal cord microstructure, plasticity, and functional connectivity. Studies that highlight translational approaches and multidisciplinary strategies bridging basic science and clinical practice are particularly encouraged.

This Special Issue seeks to foster a deeper understanding of SCI and promote the development of mechanism-based treatments for individuals living with SCI and related disorders.

#### **Guest Editor**

Dr. Corentin Dauleac

Hopital Neurologique et Neurochirurgical Pierre Wertheimer, Lyon, France

### Deadline for manuscript submissions

31 March 2026



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/243812

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





# **About the Journal**

# Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

## Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).